Estradiol increases angiotensin II type 1 receptor in hearts of ovariectomized rats

Vincent Ricchiuti, Christine G Lian, Eveline M Oestreicher, Loc Tran, James R Stone, Ellen W Seely, Gordon H Williams and Gail K Adler

Division of Endocrinology, Diabetes and Hypertension, Department of Medicine, Harvard Medical School, Brigham and Women’s Hospital, 221 Longwood Avenue, Boston, Massachusetts 02115, USA

1Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA

(Correspondence should be addressed to V Ricchiuti; Email: vricchiuti@partners.org)

Abstract

We tested the hypothesis that 17β-estradiol (E2) has dual effects on the heart, increasing levels of proteins thought to have beneficial cardiovascular effects (e.g. endothelial nitric oxide (NO) synthase (eNOS)) as well as those thought to have detrimental cardiovascular effects (e.g. type 1 angiotensin II (Ang II) receptor (AT1R)). Ovariectomized Wistar rats consuming a high-sodium diet received one of four treatments (n=7 per group): group 1, placebo pellets; group 2, E2 (0.5 mg/pellet, 21-day release); group 3, NOS inhibitor, N\textsuperscript{\textomega}-nitro-l-arginine-methyl-ester (l-NAME; 40 mg/kg per day for 14 days) plus Ang II (0.225 mg/kg per day on days 11–14); group 4, E2 plus l-NAME/Ang II. E2 increased cardiac levels of estrogen receptors ESR1 and ESR2, an ESR-associated membrane protein caveolin-3, eNOS, and phosphorylated (p)eNOS, thus, exerting potentially beneficial cardiovascular effects on NO. However, E2 also increased cardiac levels of proteins associated with cardiovascular injury and inflammation including, AT1R, protein kinase C delta (PRKCD), phosphorylated PRKCD, and phosphorylated extracellular signal regulated kinase (pMAPK)3/1, plasminogen activator inhibitor-1 (PAI-1), osteopontin and ED-1, a monocyte/macrophage-specific protein. E2 treatment led to similar protein changes in the hearts of l-NAME/Ang II-treated rats except that the increase in pеNOS was prevented, and l-NAME/Ang II and E2 had additive effects in increasing cardiac PRKCD and PAI-1. Thus, the highest levels of cardiac PAI-1 and PRKCD occurred in l-NAME/Ang II-treated rats receiving E2. In summary, E2 treatment increased cardiac expression of AT1R as well as the expression of pro-inflammatory and prothrombotic factors.

Journal of Endocrinology (2009) 200, 75–84

Background

The incidence of cardiovascular disease among women is low before menopause and steadily increases after the onset of menopause (Mendelsohn & Karas 1999). This increase is believed to result in part from the loss of endogenous estrogen and its associated cardioprotective effects (Stampfer et al. 1991). In observational human studies, estrogen replacement therapy in postmenopausal women is associated with a reduced risk of cardiovascular disease (Pinto et al. 1997). However, the Women’s Health Initiative (WHI) study (Rossouw et al. 2002) and the Heart and Estrogen/Progestin Replacement Study (Hulley et al. 1998) do not support the concept that hormone replacement therapy protects the cardiovascular system and, in fact, suggest the opposite view that such therapy may increase the risk of cardiovascular disease. Further analysis of the WHI data suggests that estrogen plus progesterone therapy was beneficial in healthy, young postmenopausal women, but increased cardiovascular risk when treatment was initiated in older postmenopausal women with established coronary artery disease (Herrington et al. 2000, Manson et al. 2003). The reasons for the disparate results regarding the cardiovascular effects of estrogen are controversial in part due to an incomplete understanding of the mechanism underlying estrogen’s effects on the cardiovascular system.

Many experimental studies in animals and isolated cells support the belief that estrogen protects the cardiovascular system (Huang et al. 2000) via activation of estrogen receptors (ESR)-1 and 2 (Mendelsohn & Karas 1999). Animal studies show beneficial effects of 17β-estradiol (E2) on atherosclerosis (Hayashi et al. 1992), inflammation (Koh 2002), and endothelial or vascular function (Gorodecki et al. 1995, Crews & Khalil 1999). Studies also demonstrate that estrogen modulation of endothelial nitric oxide (NO) synthase (eNOS) may be a mechanism of cardiac protection (Brunner et al. 2003, Khalil 2005).

Other studies suggest that estrogen activates the renin–angiotensin (Ang)–aldosterone system (RAAS), which could be a mechanism of cardiac injury. In humans, estrogen increases circulating levels of Ang II (Schunkert et al. 1997) and intrarenal Ang II activity (Seely et al. 2004), which is associated with a...
decrease in renal blood flow. In animal models of cardiovascular injury due to an activated RAAS, estrogen increases stroke and renal injury (Stier et al. 2003, Oestreicher et al. 2006). This increase in renal injury is associated with an increase in renal cortical levels of Ang II type 1 receptor (AT1R) protein and mRNA (Oestreicher et al. 2006).

As estrogen stimulates expression of some proteins that might have beneficial cardiovascular effects as well as others that might have detrimental effects, the goal of this study was to determine the balance of E2 effects on cardiac proteins involved in the early steps of cardiac injury. We examined the effects of E2 replacement in ovariectomized (OVX) rats on cardiac levels of eNOS, AT1R, and AT1R signaling pathways, and inflammatory and prothrombotic proteins. Furthermore, we tested the hypothesis that the adverse cardiac effects of E2 would predominate in a rodent model of cardiovascular injury induced by high Ang II and impaired NO production (Rocha et al. 2000, Martinez et al. 2002, Oestreicher et al. 2003). In this rat model, treatment with Ang II and the NOS inhibitor Nω-nitro-l-arginine-methyl-ester (l-NAME) causes cardiac inflammation and increases the prothrombotic factor plasminogen activator inhibitor (PAI-1; Oestreicher et al. 2003).

Materials and Methods

Experimental animals

Experiments used 10-week-old female Wistar rats (Charles River Lab, Wilmington, MA, USA) that underwent bilateral ovariectomies (OVX). Rats had ad libitum access to drinking fluid. They were housed in individual metabolic cages in a climate-controlled environment (22 ± 1 °C) with a 12 h light:12 h darkness cycle. All rats received 1% NaCl to drink. Rats were killed at the end of the 14-day treatments without respect to timing of the 4-day estrous cycle and the hearts were collected and frozen immediately. At this time, blood was also collected for determination of E2 and aldosterone levels. All experimental procedures met guidelines of the Institutional Animal Care and Use Committee at Harvard University.

Experimental procedures

We examined the following groups of rats receiving Purina Lab Chow 5001 (Ralston Purina Co., St Louis, MO, USA) and 1% NaCl to drink: 1) OVX rats implanted with pellets containing placebo and minipumps containing saline, n = 7; 2) OVX rats implanted with E2 pellets, n = 7; 3) OVX rats implanted with placebo pellets and receiving l-NAME/Ang II treatment, n = 7; and 4) OVX rats implanted with E2 pellets and receiving l-NAME/Ang II treatment, n = 7. Pellets containing E2 (#E121, Innovative Research of America, Sarasota, FL, USA, 0.5 mg/pellet, 21-day release) or placebo (#C111, Innovative Research of America) were implanted subcutaneously in each rat 7–10 days after ovariectomy. These E2 pellets were designed to achieve plasma estradiol levels in the high–normal physiological range for cycling female rats (100–150 pg/ml). One week after implantation of the pellets, animals were treated with l-NAME/Ang II as described previously (Oestreicher et al. 2006). Briefly, rats received drinking water containing 1% NaCl. l-NAME (Sigma, 40 mg/kg per day) was administered for 14 days via a subcutaneously implanted pellet (Innovative Research of America). Saline or Ang II (Sigma, 0.225 mg/kg per day) was administered via Alzet osmotic minipumps (Model 2001, Durect Corporation, Cupertino, CA, USA; 1·0 µl/h, 7 days) for the final 3 days. Pellets and minipumps were implanted under general anesthesia using isoflurane. On day 14, death was induced by administration of isoflurane followed by the immediate collection of blood and hearts.

Histological evaluation

The heart tissue for histological evaluation was processed into paraffin blocks. The heart sections (5 µm) were stained with hematoxylin and eosin and examined using light microscopy by a pathologist unaware of the treatment group assignment. The histologic sections of the hearts were scored for myocardial damage on a scale from 0 to 4 as follows: 0, normal histology; 1, focal interstitial inflammatory infiltrates without myocyte injury; 2, a single focus of interstitial inflammatory infiltrate associated with myocyte injury; 3, two or three foci of interstitial inflammatory infiltrates associated with myocyte injury; and 4, four or more foci of inflammatory infiltrates associated with myocyte injury.

Measurements and assays

Daily food intake, water intake, body weight, and urine output were recorded. Systolic blood pressure (SBP) was measured in conscious animals by tail-cuff plethysmography (Blood Pressure Analyzer, Model 179, ITTC Life Science, Woodland Hills, CA, USA). Plasma estradiol was measured with the DPC Double Antibody Estradiol (analytical sensitivity of 1·4 pg/ml) as described previously (Oestreicher et al. 2006). Aldosterone was measured using the DPC Coat–A–Count Aldosterone RIA as described previously (Turchin et al. 2006; DPC Diagnostic Products, Los Angeles, CA, USA).

Western blot analysis

The heart tissues were homogenized in 1 ml ice-cold lysis solution (Bio-Rad cell lysis kit – catalog #171–304012). The ground tissue was transferred to a clean microcentrifuge tube and frozen at −70 °C. Homogenates were then thawed and sonicated on ice (Fisher Sonic Dismembrator, model 300, Fisher Scientific, Pittsburgh, PA, USA). Samples were then centrifuged at 4800 g for 4 min at 4 °C. Supernatant was collected without disturbing the pellets. Protein concentration in the supernatant was determined using modified Lowry assay (RC DC protein assay; Bio-Rad catalog #500–0119, Bio-Rad). Supernatants (20 µg of protein concentration) were combined
at least 1:2 with sample buffer (62.5 mM Tris, pH 6.8, 2% SDS, 25% glycerol, 0.01% bromophenol blue, 200 mM \(\beta\)-mercaptoethanol), heated at 95 °C for 4 min, and size fractionated by electrophoresis on 12.5% SDS-polyacrylamide gels using 1 × of the following 10 × buffer: 250 mM Tris base, 1.92 M glycine, 34.7 mM SDS. Proteins were electrophoretically transferred to Hybond-ECL nitrocellulose membranes (Amersham Bioscience) using the following transfer buffer: 25 mM Tris, 192 mM glycine, 20% v/v methanol, pH 8.3. The membranes were blocked in 5% nonfat dried milk in PBS-T (80 mM Na2HPO4 anhydrous, 20 mM NaH2PO4, 100 mM NaCl, and 0.1% Tween 20) for 1 h at room temperature on an orbital shaker. Primary antibody incubation was incubated overnight at 4 °C with antibody diluent consists of 1% nonfat dried milk in PBS-T. Equal loading was assessed by reprobing membranes with an antibody to \(\beta\)-actin (1:20,000; Clone AC-15, Sigma). After overnight incubation, the bound antibody was detected by enhanced chemiluminescence (Western Lightning Reagent Plus, Perkin-Elmer Life Sciences, Boston, MA, USA) with HRP-conjugated goat anti-rat IgG (sc-2006, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA, dilution 1:3000), or goat anti-mouse IgG (sc-2005, Santa Cruz, dilution 1:5000), or goat anti-rabbit IgG (sc-2004, Santa Cruz, dilution 1:5000). Developed X ray films were scanned and densitometric analysis was performed with the ImageQuant 5.2 software (Molecular Dynamics, Piscataway, NJ, USA). To control for inter-gel variations we used the following procedure. On each 15-well mini-gels, we analyzed three to four samples from each of the four treatment groups; two samples were used for normalization between mini-gels. All western blots were re-probed once with anti-\(\beta\)-actin antibody and the protein of interest was normalized to \(\beta\)-actin to correct for loading variability. Samples were re-analyzed on a separate western blot to confirm results. All values were expressed relative to the average of the OVX rats receiving control treatment.

**Antibodies**

We used the following western blot: ESR1 (#GR17, Calbiochem, San Diego, CA, USA, dilution 1:1000); ESR2 (#sc-8974, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA, dilution 1:5000); and AT1R (#sc-1173, Santa Cruz, dilution 1:1000). The specificity of the antibody to AT1R was confirmed by receptor binding assays as described previously (Oestreicher et al. 2006); CAV3 (#RDI-CAVEOL3abrx, Research Diagnostics, Concord, MA, USA, dilution 1:10 000); eNOS (#N30030/L14, BD Transduction Laboratories, San Jose, CA, USA, dilution 1:2500); PRKCD (#610397BD Transduction Laboratories, dilution 1:1000); PAI-1 (#612024, BD Transduction Laboratories, dilution 1:2500); ED-1 (#554954, BD Transduction Laboratories, dilution 1:1000); phosphorylated protein kinase C (pPRKC; #9371S, Cell Signaling, Danvers, MA, USA, dilution 1:1000); and pMAPK3/1 (#9101S, Cell Signaling, dilution 1:2000); peNOS (9571S, Cell Signaling, dilution 1:1000). The peNOS antibody is directed against phosphorylated serine 1177. This site is specific for eNOS activation.; and OPN (#ab8448, Abcam, Cambridge, MA, USA, dilution 1:5000).

**Statistical analysis**

The statistical significance of the differences between the group means for the data were determined by one-way ANOVA followed by Newman–Keuls post hoc test for multiple comparisons. \(P \leq 0.05\) was considered statistically significant. Values are expressed as mean ± S.E.M.

**Results**

**1-NAME, Ang II, and E2 effects on cardiac histology**

Treatment with 1-NAME and Ang II caused a significant increase in cardiac damage compared with control treatment (Figs 1 and 2). Damaged hearts showed inflammatory infiltrates associated with myocyte injury (Fig. 1C and D). E2 treatment had no significant effect on cardiac histology in the control NaCl-treated OVX rats or in the 1-NAME/Ang II-treated OVX rats (Figs 1B, D and 2).

**E2 effects in healthy young OVX rats**

OVX rats receiving 1% NaCl in the drinking water were implanted with subcutaneous pellets containing either placebo or E2. After 14 days, E2 levels were significantly higher in the OVX rodents receiving E2 when compared with those not receiving E2 (Table 1). Consistent with the known effects of E2 in rodents, OVX rats receiving E2 had lower body weights, higher uterine weights, and higher uterine/body weight ratios than OVX rats not receiving E2 (Table 1). SBP and heart weights were similar in the E2- and placebo-treated OVX rats (Table 1).

Protein levels of ESR1 (Fig. 3A) and ESR2 (Fig. 3B) were increased in the heart tissues of OVX rats receiving E2 when compared with those not receiving E2. After 14 days, E2 levels were significantly higher in the OVX rodents receiving E2 when compared with animals that did not receive E2 (Table 1). Furthermore, E2 treatment increased cardiac levels of CAV3 (1.55-fold increase for ESR1, \(P<0.05\) and 1.6-fold increase for ESR2, \(P<0.001\)). Additionally, protein levels of CAV3 (1.55-fold increase, \(P<0.01\), Fig. 4C), a caveolae protein that is part of the E2 signaling pathway in cardiomyocytes. Plasma aldosterone levels were significantly elevated in rats receiving E2 when compared with animals that did not receive E2 (Table 1). Furthermore, E2 treatment increased protein levels of AT1R in the heart homogenates when compared with OVX rats not receiving E2 (Fig. 5A, \(P<0.05\)).

Cardiac levels of PRKCD were increased by 2.5-fold (Fig. 5B, \(P<0.01\)), pPRKC by 2.2-fold (Fig. 5C, \(P<0.05\)), and pMAPK3/1 by 1.3-fold (Fig. 5D, \(P<0.05\)) in rats implanted with E2 pellets versus those implanted with placebo pellets.
We determined the effect of E2 on cardiac expression of PAI-1 (an E2-responsive prothrombotic factor (Smith et al. 2004), the chemokine osteopontin (OPN), and ED-1 (a protein expressed by monocytes/macrophages)). The cardiac levels of PAI-1 protein were increased in rats receiving E2 when compared with those not receiving E2 (Fig. 6A, P<0.01). Furthermore, E2 treatment significantly increased cardiac levels of ED-1 (Fig. 6B, P<0.01) and OPN (Fig. 6C, P<0.05). Thus, E2 increases prothrombotic and inflammatory factors in cardiac tissue in OVX female rats that were otherwise healthy.

E2 effects in OVX rats receiving L-NAME/Ang II

OVX rats treated with L-NAME/Ang II plus E2 had higher blood levels of E2, decreased body weight, increased uterine weight, and increased uterine/body weight ratio compared with OVX rats receiving L-NAME/Ang II (Table 1). E2 treatment did not affect the heart weight or SBP of L-NAME/Ang II-treated rats. As occurred in rats drinking 1% NaCl, E2 treatment increased cardiac levels of ESR1 and ESR2 in rats receiving L-NAME/Ang II, a treatment that itself did not affect ESR levels (data not shown).

L-NAME/Ang II treatment alone did not alter cardiac levels of eNOS, peNOS, or AT1R, nor plasma levels of aldosterone. By contrast, E2 treatment increased protein levels of eNOS (Fig. 7A) in the hearts from L-NAME/Ang II-treated rats. The magnitude of this E2 effect in the L-NAME/Ang II/NaCl-treated rats was similar to that observed in OVX rats drinking 1% NaCl. However, E2 treatment did not increase peNOS levels in rats receiving L-NAME/Ang II (Fig. 7C). As occurred in OVX rats drinking 1% NaCl, E2 treatment increased plasma aldosterone and cardiac AT1R levels in rats receiving L-NAME/Ang II/NaCl.
Both E2 and L-NAME/Ang II treatment increased cardiac levels of PRKCD and PAI-1, and these effects were additive (Fig. 8A and B). Finally, while E2 increased cardiac levels of pPKC, pMAPK3/1, ED-1, and OPN in L-NAME/Ang II/NaCl-treated animals as occurred in the rats receiving 1% NaCl alone, L-NAME/Ang II treatment did not affect these factors and there was no additive effect of these two treatments (data not shown).

**Discussion**

These studies determined the cardiac effects of E2 treatment in OVX female rats. In OVX, but otherwise healthy female rats, E2 increased cardiac expression of eNOS and peNOS, which was expected to enhance NO production and, thus, have a beneficial cardiac effect. However, E2 also increased cardiac levels of AT1R and other factors (PAI-1, OPN, ED-1, and PRKCD) known to induce inflammation, thrombosis, and/or cardiac damage. In the model of cardiovascular injury induced by Ang II and NOS inhibition, the E2-mediated increase in peNOS was lost, while E2-mediated increases in cardiac AT1R, PAI-1, OPN, ED-1, and PRKCD were maintained. Furthermore, E2 acted additively with L-NAME/Ang II treatment to increase cardiac levels of PAI-1 and PRKCD. Thus, these data demonstrate that E2 increases the expression of cardiac proteins that have beneficial cardiac effects (peNOS) as well as those that have detrimental cardiac effects (e.g. AT1R and PAI-1). When the beneficial effects of E2 on peNOS were blocked with a NOS inhibitor, the detrimental effects of E2 dominated.

Our results are consistent with the well-known beneficial effect of E2 to increase peNOS leading to increased NO and improved vasodilation (Reis et al. 1994, Collins et al. 1995). We also demonstrated an increase in MAPK3/1 with E2 treatment. This latter result is consistent with studies demonstrating the activation of the MAPK3/1 pathway by estrogen in multiple cell types and tissues, including endothelial cells (Gorodeski et al. 1995), neuronal cells (Alexaki et al. 2006), smooth muscle cells (Keyes et al. 1996), and myocardium (Patten et al. 2004, Pedram et al. 2005). These non-genomic effects of estrogen are mediated via its two receptors, ESR1 and ESR2 (Mendelsohn & Karas 1999). We demonstrated that E2 increased expression of both ESR1 and ESR2 in the heart tissues, consistent with other reports showing that E2 replacement increases expression of ESR1, and ESR2 in the heart tissues from aged rats (Xu et al. 2003). In our study, the increase of ESR2 was greater than that of ESR1, possibly due to differential effects of estradiol on synthesis and/or degradation of ESR subtypes (Barchiesi et al. 2004). ESRs interact with the caveolae anchoring protein CAV3 to mediate the rapid, non-genomic effects of estrogen and other steroids, and increasing CAV3 levels tends to inhibit eNOS activation (Hisamoto & Bender 2005). Estrogen treatment increased CAV3 in our studies, raising the possibility that estrogen-mediated changes in caveolin levels modulate the effects of estrogens and other steroids on intracellular signaling pathways (Feron & Kelly 2001, Damy et al. 2004, Williams & Lisanti 2004).

The observation that E2 increases protein levels of AT1R in the hearts of healthy, OVX rats and L-NAME/Ang II-treated rats is consistent with the reports that E2 increases AT1R expression in the uteri of healthy rats (Krishnamurthi et al. 1999) and in the renal cortex of rats receiving L-NAME/Ang II (Oestreicher et al. 2006). In the latter study, the level of AT1R expression correlated with proteinuria (Oestreicher et al. 2006). Similarly, estrogen has been shown to increase cardiac and renal injury in other animal models characterized by an activated RAAS. In the stroke prone spontaneously hypertensive rat, ovariectomy reduced stroke and renal injury, while estrogen replacement increased this injury (Stier et al. 2003). The hypertensive mRen2.Lewis rat is a transgenic rat strain carrying the mouse ren-2 renin gene backcrossed into the inbred Lewis rat. In the hypertensive mRen2.Lewis female rat, ovariectomy reduced proteinuria, renal injury, and blood levels of the inflammatory marker C-reactive protein in older, 64-week-old mRen2.Lewis rats on a high-salt diet (Yamaleyeva et al. 2007). Our observation that E2 and L-NAME/Ang II treatment have additive effects on cardiac PAI-1 is consistent with these studies, and together these

### Table 1 Effects of E2 treatment on body, uterine and heart weights, blood pressure, and E2 and aldosterone levels. All values are mean ± S.E.M.; n=7. The statistical significance of the differences between group means for the data was determined by one-way ANOVA followed by Newman–Keuls post hoc test for multiple comparisons.

<table>
<thead>
<tr>
<th></th>
<th>Placebo</th>
<th>E2</th>
<th>Placebo</th>
<th>E2</th>
</tr>
</thead>
<tbody>
<tr>
<td>E2 (pg/ml)</td>
<td>11.2±2.1</td>
<td>21.2±6.130±8*</td>
<td>10.3±0.9</td>
<td>16.8±0.85±7*</td>
</tr>
<tr>
<td>ALDO (ng/dl)</td>
<td>15.3±4.8</td>
<td>11.0±4.0</td>
<td>15.3±7.0</td>
<td>15.8±5.8*</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>111.0±5.0</td>
<td>255.9±11.0*</td>
<td>114.0±0.2</td>
<td>1.1±0.04</td>
</tr>
<tr>
<td>BW (g)</td>
<td>324.0±6.0</td>
<td>1.1±0.03</td>
<td>0.10±0.01</td>
<td>0.70±0.09*</td>
</tr>
</tbody>
</table>
| UW (g)            | 0.10±0.01| 0.70±0.09*| 0.33±0.01| 2.70±0.23*
| BW/BW (mg/g)      | 0.31±0.01| 2.70±0.09*| 0.33±0.01| 2.72±0.32*|

E2, estradiol; ALDO, aldosterone; SBP, systolic blood pressure; UW, uterine weight. *P≤0.05 for OVX/placebo versus OVX/E2. †P≤0.05 for OVX/L-NAME/Ang II/E2 versus OVX/placebo. **P≤0.05 for OVX/E2 versus OVX/L-NAME/Ang II/E2.

We demonstrated an increase in pMAPK3/1 with E2 and PAI-1 and PRKCD. Thus, these data demonstrate that E2 increased cardiac levels of AT1R and other factors (PAI-1, NaCl alone, L-NAME/Ang II treatment did not affect these factors and there was no additive effect of these two treatments (data not shown).
animal studies demonstrate that E2 promotes Ang II-mediated cardiovascular injury. AT1R is expressed in endothelial cells, vascular smooth muscle cells, and cardiomyocytes (Bueno et al. 2000). Additional studies are needed to determine which cell types within the heart demonstrate altered AT1R expression with estrogen treatment. Our observation that E2 increases AT1R protein provides a potential mechanism for the increase in intrarenal Ang II activity leading to a reduction in renal blood flow in postmenopausal women treated with estrogen (Seely et al. 2004).

In contrast to our observations, estrogen replacement was reported to decrease cardiac AT1R, increase cardiac Ang II type 2 receptor, and improve heart remodeling in 1-year-old OVX rats (Xu et al. 2003). Estrogen also decreased AT1R levels in the adrenal and pituitary glands of OVX rats

Figure 3 E2 treatment increases ESR1 and ESR2 protein expression in the heart tissue of OVX rats. Western blot of heart tissue showing results for three representative animals (20 μg of total protein per lane, each lane represent an individual animal) from OVX rats receiving placebo (OVX) and OVX E2-treated rats (E2). (A) 66 kDa band for ESR1 and (B) 54 kDa band for ESR2.

Figure 4 E2 treatment increases eNOS, peNOS, and CAV3 protein expression in the heart tissue of OVX rats. Western blot of heart tissue showing results for three representative animals (20 μg of total protein per lane, each lane represent an individual animal) from OVX rats receiving placebo (OVX) and OVX E2-treated rats (E2). (A) 140 kDa band for eNOS, (B) 140 kDa band for peNOS, and (C) 22 kDa band for CAV3.
It is likely that the effects of estrogen on AT$_1$R expression and Ang II–mediated injury differ depending on the experimental animal model. Factors such as age, genotype, dietary sodium intake, and underlying activity of the RAAS or NO system may modify the effects of estrogen. In our study, L-NAME treatment blocked the beneficial effects of E$_2$ on peNOS levels. Additionally, as E$_2$ increased cardiac levels of the Ang II receptor AT$_1$R, the co-administration of Ang II in our rat model further amplified the adverse cardiac effects of E$_2$ treatment.

In the present study, E$_2$ treatment increased plasma aldosterone levels in OVX rats receiving either placebo or L-NAME/Ang II. It is unlikely that E$_2$ increased systemic aldosterone levels through increases in adrenal AT$_1$R as other investigators have shown that E$_2$ decreases AT$_1$R levels in adrenal tissue (Wu et al. 2003). However, this increase may result from E$_2$–mediated increases in angiotensinogen leading to increases in Ang II, and thus increased adrenal aldosterone production (Klett et al. 1992, Gallagher et al. 1999).

It is now well established that aldosterone causes cardiovascular injury with activation of the mineralocorticoid receptor causing increases in PAI-1, vascular injury, and inflammation, as well as myocardial necrosis, inflammation, and fibrosis (Rocha et al. 2000, 2002, Oestreicher et al. 2003). Blockade of the mineralocorticoid receptor markedly reduces cardiovascular injury caused by L-NAME/Ang II treatment (Rocha et al. 2000, Oestreicher et al. 2003). Given the effects of E$_2$ on AT$_1$R and aldosterone, it would be of interest to determine whether mineralocorticoid receptor blockade prevents the adverse cardiovascular effects of E$_2$.

There are some limitations to these studies. Consistent with previous studies (Rocha et al. 2000), we did not detect a significant effect of Ang II on aldosterone levels in animals (Wu et al. 2003).
receiving L-NAME and a high-salt diet. This is likely due in part to our using a low dose of Ang II that is a subpressor dose in the absence of L-NAME treatment. However, this Ang II dose suppresses plasma renin activity (Rocha et al. 2000) and it is possible that increases in aldosterone production would be detected using a more sensitive method such as 24-h urinary aldosterone levels. Our studies used 0.5 mg, 21-day E2 pellets that are commonly used to assess effects of E2 and are designed to raise E2 levels into the range observed in pro-estrus (50–150 pg/ml; Klett et al. 1992). This experimental design did not allow us to determine whether there are different E2 dose response characteristics for the beneficial and detrimental effects of E2 in the presence of L-NAME and Ang II.

**Figure 7** Effect of E2 on eNOS, peNOS, and AT1R expression in the hearts of OVX animals treated with l-NAME/Ang II when compared with E2 effects in absence of l-NAME/Ang II. Western blot of heart tissue showing results for three representative animals (20 μg of total protein per lane, each lane represent an individual animal) from OVX rats receiving placebo (OVX), OVX E2-treated rats (E2), l-NAME/Ang II and placebo (LN/All), and l-NAME/Ang II and E2 treatments (LN/All/E2). (A) 140 kDa band for eNOS, (B) 43 kDa band for AT1R, and (C) 140 kDa band for peNOS. For ease of comparison, OVX and E2 data from Figs 4A, B and 5A are reproduced in this figure.

**Figure 8** Effect of E2 on PRKCD and PAI-1 expression in the hearts of OVX animals treated with l-NAME/Ang II when compared with E2 effects in absence of l-NAME/Ang II. Western blot of heart tissue showing results for three representative animals (20 μg of total protein per lane, each lane represent an individual animal) from OVX rats receiving placebo (OVX), OVX E2-treated rats (E2), l-NAME/Ang II and placebo (LN/All), and l-NAME/Ang II and E2 treatments (LN/All/E2). (A) 78 kDa band for PRKCD and (B) 66 kDa band for PAI-1. For ease of comparison, OVX and E2 data from Figs 5B and 6A are reproduced in this figure.
cardiac effects of E2. The wide range of E2 values in the E2-treated rats may have introduced variability and the presence of low E2 levels of ~10–12 pg/ml in the OVX rats may have limited our ability to detect E2 effects. These levels are consistent with the published reports of E2 (11.3 ± 3.6 pg/ml) in OVX rats and are likely attributable to non-ovarian sources of E2 (Hugel et al. 1999). In addition, our experimental approach did not allow us to determine whether the cardiac effects of E2 are due to direct effects of E2 or are mediated through other factors. For example, E2 treatment increased the cardiac AT1R levels and the activation of either ESRs or AT1R can increase PRKC pathways and PAI-1 (Smith et al. 2004, Alexaki et al. 2006). In our study, we used cardiac PAI-1 levels as a marker of early cardiovascular injury as described previously (Oestreich et al. 2003). While E2 treatment increased PAI-1 and other mediators of cardiovascular injury, the increase in these factors were not associated with a detectable increase in cardiac injury histopathology, possibly due to relative insensitivity of this method and to the relatively short duration of treatment.

These findings indicate that E2 has diverse effects on the heart, some of which are beneficial (increases in eNOS and peNOS), and others of which are detrimental (increases in AT1R, PAI-1, and cardiac inflammation). The relative balance of these effects may determine whether the overall effect of E2 is beneficial or detrimental. Further elucidations of the factors that modify this balance are needed. The finding that E2 increases cardiac expression of AT1R has relevance to the mechanisms underlying the adverse cardiac effects of estrogen therapy in postmenopausal women.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by NIH training grants 5T32HL007699 and DK07529, and NIH research grants HL-63423, HL-67332K24, RR018613, R01 HL67332, and HL-069208. This work was supported by NIH training grants 5T32HL007699 and DK07529, and NIH research grants HL-63423, HL-67332K24, RR018613, R01 HL67332, and HL-069208. Funding sources of E2 (Hugel et al. 1999). In addition, our experimental approach did not allow us to determine whether the cardiac effects of E2 are due to direct effects of E2 or are mediated through other factors. For example, E2 treatment increased the cardiac AT1R levels and the activation of either ESRs or AT1R can increase PRKC pathways and PAI-1 (Smith et al. 2004, Alexaki et al. 2006). In our study, we used cardiac PAI-1 levels as a marker of early cardiovascular injury as described previously (Oestreich et al. 2003). While E2 treatment increased PAI-1 and other mediators of cardiovascular injury, the increase in these factors were not associated with a detectable increase in cardiac injury histopathology, possibly due to relative insensitivity of this method and to the relatively short duration of treatment.

These findings indicate that E2 has diverse effects on the heart, some of which are beneficial (increases in eNOS and peNOS), and others of which are detrimental (increases in AT1R, PAI-1, and cardiac inflammation). The relative balance of these effects may determine whether the overall effect of E2 is beneficial or detrimental. Further elucidations of the factors that modify this balance are needed. The finding that E2 increases cardiac expression of AT1R has relevance to the mechanisms underlying the adverse cardiac effects of estrogen therapy in postmenopausal women.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by NIH training grants 5T32HL007699 and DK07529, and NIH research grants HL-63423, HL-67332K24, RR018613, R01 HL67332, and HL-069208. This work was supported by NIH training grants 5T32HL007699 and DK07529, and NIH research grants HL-63423, HL-67332K24, RR018613, R01 HL67332, and HL-069208. Funding sources of E2 (Hugel et al. 1999). In addition, our experimental approach did not allow us to determine whether the cardiac effects of E2 are due to direct effects of E2 or are mediated through other factors. For example, E2 treatment increased the cardiac AT1R levels and the activation of either ESRs or AT1R can increase PRKC pathways and PAI-1 (Smith et al. 2004, Alexaki et al. 2006). In our study, we used cardiac PAI-1 levels as a marker of early cardiovascular injury as described previously (Oestreich et al. 2003). While E2 treatment increased PAI-1 and other mediators of cardiovascular injury, the increase in these factors were not associated with a detectable increase in cardiac injury histopathology, possibly due to relative insensitivity of this method and to the relatively short duration of treatment.

These findings indicate that E2 has diverse effects on the heart, some of which are beneficial (increases in eNOS and peNOS), and others of which are detrimental (increases in AT1R, PAI-1, and cardiac inflammation). The relative balance of these effects may determine whether the overall effect of E2 is beneficial or detrimental. Further elucidations of the factors that modify this balance are needed. The finding that E2 increases cardiac expression of AT1R has relevance to the mechanisms underlying the adverse cardiac effects of estrogen therapy in postmenopausal women.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This work was supported by NIH training grants 5T32HL007699 and DK07529, and NIH research grants HL-63423, HL-67332K24, RR018613, R01 HL67332, and HL-069208. This work was supported by NIH training grants 5T32HL007699 and DK07529, and NIH research grants HL-63423, HL-67332K24, RR018613, R01 HL67332, and HL-069208.

References


Received in final form 10 September 2008
Accepted 16 September 2008
Made available online as an Accepted Preprint 17 October 2008